Hodgkin lymphoma, version 2.2015 Journal Article
| Authors: | Hoppe, R. T.; Advani, R. H.; Ai, W. Z.; Ambinder, R. F.; Aoun, P.; Bello, C. M.; Benitez, C. M.; Bierman, P. J.; Blum, K. A.; Chen, R.; Dabaja, B.; Forero, A.; Gordon, L. I.; Hernandez-Ilizaliturri, F. J.; Hochberg, E. P.; Huang, J.; Johnston, P. B.; Khan, N.; Maloney, D. G.; Mauch, P. M.; Metzger, M.; Moore, J. O.; Morgan, D.; Moskowitz, C. H.; Mulroney, C.; Poppe, M.; Rabinovitch, R.; Seropian, S.; Tsien, C.; Winter, J. N.; Yahalom, J.; Burns, J. L.; Sundar, H. |
| Article Title: | Hodgkin lymphoma, version 2.2015 |
| Abstract: | Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment. © JNCCN - Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 13 |
| Issue: | 5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2015-05-01 |
| Start Page: | 554 |
| End Page: | 586 |
| Language: | English |
| PROVIDER: | scopus |
| PMCID: | PMC4898052 |
| PUBMED: | 25964641 |
| DOI: | 10.6004/jnccn.2015.0075 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 6 December 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work